YMZBY yields 2.10% · PFE yields 6.13%● Live data
📍 YMZBY pulled ahead of the other in Year 1
Combined, YMZBY + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of YMZBY + PFE for your $10,000?
Yamazaki Baking Co., Ltd., through its subsidiaries, manufactures and sells baked goods in Japan. Its products include loaf bread, sweet buns, donuts, hard rolls, and Danish pastries; Japanese, Western style, and rice-derived and based confectionery; processed bread and noodles, prepared rice, and side dishes; and chocolates, candies, stevia-based and other sweeteners, snack foods, and soup and soup stocks, as well as jams, marmalades, jelly and yokan products, and ready-to-eat curries in retort pouches. The company also manufactures biscuits, cookies, crackers, and frozen bread dough; provides coffee and juice under the Yamazaki brand; creams, curry fillings, stuffing for Chinese filled buns, croquettes, meat patties, and mayonnaise products; and prepared mixes for bread, tempura, and fried chicken, as well as sells products procured from other companies. In addition, it is involved in the manufacture and sale of cleaning and disinfecting agents for food production equipment; operation of bread and pastry shops, restaurants, convenience stores, and supermarkets; provision of retail bakery and cafe management, in-store bakery management, general truck transport and freight forwarding, and insurance services; and design of equipment for manufacturing bread and confectionery, installation of production facilities, and other services. Further, the company offers logistics management services; and manufactures and sells stevia-based and other sweeteners. As of December 31, 2021, it operated 1,389 stores. Yamazaki Baking Co., Ltd. was incorporated in 1948 and is headquartered in Tokyo, Japan.
Full YMZBY Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.